Get started
Author

Maria Loose

Observed name: M. Loose
ORCID: 0000-0003-2319-7734
Observed ORCID: 0000-0003-2319-7734
OpenAlex ID: A5001432303
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
2023 · Sylvie Lorenzen, Thorsten Oliver Götze, et al. · Journal of Clinical Oncology · 248
Activation of the unfolded protein response by Listeria monocytogenes: Listeria and UPR
2012 · Helena Pillich, Maria Loose, et al. · Cellular Microbiology · 121
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
2022 · Ralf-Dieter Hofheinz, Kirsten Merx, et al. · Journal of Clinical Oncology · 106
Pneumococcal Hydrogen Peroxide–Induced Stress Signaling Regulates Inflammatory Genes
2014 · Maria Loose, Martina Hudel, et al. · The Journal of Infectious Diseases · 39
PDF
Diverse roles of endoplasmic reticulum stress sensors in bacterial infection
2016 · Helena Pillich, Maria Loose, et al. · Molecular and Cellular Pediatrics · 36
PDF
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
2024 · Thorsten O. Goetze, Alexander Reichart, et al. · Annals of Surgical Oncology · 35
PDF
Natural Bred ε2-Phages Have an Improved Host Range and Virulence against Uropathogenic Escherichia coli over Their Ancestor Phages
2021 · Maria Loose, David Sáez Moreno, et al. · Antibiotics · 28
PDF
Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli
2018 · Maria Loose, Kurt G. Naber, et al. · International Journal of Antimicrobial Agents · 28
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
2023 · Thorsten O. Goetze, Ralf‐Dieter Hofheinz, et al. · International Journal of Cancer · 26
The Lectin-like Domain of TNF Increases ENaC Open Probability through a Novel Site at the Interface between the Second Transmembrane and C-terminal Domains of the α-Subunit
2016 · Rudolf Lucas, Qiang Yue, et al. · Journal of Biological Chemistry · 26
Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria
2021 · Maria Loose, Kurt G. Naber, et al. · Urologia Internationalis · 25
PDF
Anti-Bacterial Effects of Essential Oils against Uropathogenic Bacteria
2020 · Maria Loose, Emmelie Pilger, et al. · Antibiotics · 24
PDF
Effect of Different Media on the Bactericidal Activity of Colistin and on the Synergistic Combination With Azidothymidine Against mcr-1-Positive Colistin-Resistant Escherichia coli
2020 · Maria Loose, Kurt G. Naber, et al. · Frontiers in Microbiology · 22
PDF
Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural Chelocardin
2020 · Fabienne Hennessen, Marcus Miethke, et al. · Antibiotics · 17
PDF
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
2023 · S.-E. Al-Batran, D.W. Mueller, et al. · ESMO Open · 14
PDF
Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer
2022 · Undraga Schagdarsurengin, Vanessa Breiding, et al. · Frontiers in Oncology · 14
PDF
Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
2024 · Michael Masetti, Salah‐Eddin Al‐Batran, et al. · International Journal of Cancer · 13
PDF
Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli
2019 · Maria Loose, Kurt G. Naber, et al. · International Journal of Antimicrobial Agents · 12
Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae
2019 · Maria Loose, Isabell Link, et al. · Antimicrobial Agents and Chemotherapy · 10
Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy
2023 · Thorsten Oliver Goetze, Alexander Stein, et al. · International Journal of Cancer · 9
PDF
Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption
2017 · Maria Loose, Kurt G. Naber, et al. · International Journal of Antimicrobial Agents · 8
Comparative transcriptomic and proteomic signature of lung alveolar macrophages reveals the integrin CD11b as a regulatory hub during pneumococcal pneumonia infection
2023 · Kristina Zec, Stephanie Thiebes, et al. · Frontiers in Immunology · 5
PDF
Fisetin Protects AgainstListeria monocytogenesInfection by Reducing the Production of Listeriolysin O
2015 · Maria Loose, Helena Pillich, et al. · The Journal of Infectious Diseases · 4
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
2026 · Sylvie Lorenzen, Thorsten Oliver Goetze, et al. · Nature Communications · 3
PDF
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial
2026 · Michael Masetti, Alexander Nieto, et al. · European Journal of Cancer · 1
PDF
Works count: 30
Citation count: 875
H-index: 14
I10-index: 19
Year
Topic
Type